Dong-A ST, represented by Min-Young Kim, announced on April 5th their intention to unveil preclinical results of 'DA-4511,' an allosteric inhibitor of SHP1 (Src homology phosphatase-1), and an innovative immunotherapeutic anticancer agent, in poster format at the American Association for Cancer Research (AACR 2024), taking place in San Diego, California from April 5th to 10th.

AACR, recognized as one of the top three cancer congresses globally alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), gathers leading experts and industry stakeholders to discuss anticancer therapy and novel drug development.

Dong-A ST's presentation will focus on 'Efficacy and Safety of DA-4511, the First-in-Class SHP1 Allosteric Inhibitor in Preclinical Studies.' The data to be revealed will demonstrate an increase in cytokine secretion by immune cells and enhancement of effector T-cell function through DA-4511. Additionally, the company plans to disclose the anticancer effects observed in animal models and the synergistic benefits of combining DA-4511 with existing immune checkpoint inhibitors such as the PD-1 antibody.

DA-4511, functioning as a SHP1 inhibitor, targets a protein tyrosine phosphatase known to inhibit phosphorylation signaling in immune cells, thereby suppressing immune function. Dong-A ST's discovery of a small molecule compound capable of selectively inhibiting SHP1 by targeting an allosteric site, thus enabling oral bioavailability, marks a significant breakthrough in the field.

Furthermore, researchers from Yonsei University will present findings on the anticancer effects of Dong-A ST's Aryl Hydrocarbon Receptor (AhR) antagonist, 'DA-4505,' in combination with anti-PD-1 immune checkpoint inhibitors.

A representative from Dong-A ST stated, "In our preclinical studies, we have validated the potential of DA-4511 as the world's first SHP1 allosteric inhibitor and an innovative immunotherapeutic agent. We have also observed increased cytokine secretion by immune cells and enhancement of effector T-cell function." They further added, "We are committed to swiftly concluding preclinical research on DA-4511 and directing our research and development (R&D) efforts towards advancing to subsequent stages."